Brachytherapy Market Report 2024

The brachytherapy market size has grown strongly in recent years. It will grow from $0.87 billion in 2023 to $0.93 billion in 2024 at a compound annual growth rate (CAGR) of 7.9%. The growth during the historic period can be attributed to increasing cancer incidence, rising awareness and efforts in early detection, growing recognition of brachytherapy's effectiveness and reduced side effects, favorable reimbursement policies across various regions, and the approval and standardization of brachytherapy procedures and devices.

The brachytherapy market size is expected to see strong growth in the next few years. It will grow to $1.27 billion in 2028 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to the customization of treatments based on genetic and molecular profiles, increasing demand driven by higher cancer incidence among elderly populations, expansion of healthcare facilities supporting brachytherapy, greater investments in cancer treatment, and a rising preference for less invasive therapies. Major trends during this period include innovations in brachytherapy techniques and equipment, advancements in personalized medicine, integration of advanced imaging technologies such as MRI and PET-CT for real-time guidance during brachytherapy procedures, growing preference for outpatient brachytherapy procedures, and advancements in brachytherapy technology.

The projected increase in cancer burden is set to drive growth in the brachytherapy market. This rise in cancer cases is attributed to factors such as aging populations, changes in lifestyle, and heightened exposure to risk factors such as tobacco use, poor dietary habits, and environmental pollutants. Brachytherapy serves as a targeted and effective treatment option for managing cancer burden, offering localized therapy tailored to various cancer types, which helps minimize treatment duration and side effects. For example, the American Cancer Society reported in January 2022 that the US is expected to see approximately 1.9 million new cancer cases and 609,360 cancer-related deaths, highlighting a significant daily impact. Globally, lung, prostate, colorectal, and breast cancers are among the most prevalent, accounting for 43% of all newly diagnosed cases. Therefore, the escalating cancer burden is expected to stimulate growth in the brachytherapy market.

Key players in the brachytherapy market are concentrating on advancing technological solutions, such as standard afterloader technology, to improve treatment accuracy and effectiveness. Standard afterloader technology automates the delivery of radioactive sources to tumor sites during brachytherapy, ensuring precise administration of radiation doses. For instance, Varian Medical Systems, a US-based medical device manufacturer, collaborated with Maastro, a US-based radiotherapy clinic, to introduce a new brachytherapy applicator in April 2024. This innovative device, partially 3D-printed and co-developed by Maastro's radiation oncologists, physicists, and Varian experts, enhances HDR brachytherapy treatment for rectal cancer. The applicator is designed to enhance tumor contact and deliver a uniform dose distribution, comparable to contact X-ray brachytherapy (CXB).

In April 2024, GT Medical Technologies Inc., a US-based medical device manufacturer, acquired Cesium-131 and related assets from Isoray Medical to strengthen its supply chain and market position. This strategic acquisition underscores GT MedTech's commitment to expanding the adoption of GammaTile in the US, leveraging Cesium-131 brachytherapy seed manufacturing capabilities. Isoray Medical, also a US-based medical device manufacturer, specializes in brachytherapy products for cancer treatment.

Major companies operating in the brachytherapy market are Siemens Healthineers, Becton Dickinson and Company, Boston Scientific Corporation, Hologic Inc., Varian Medical Systems Inc., Carl Zeiss AG, Elekta, Argon Medical Devices Inc., Sirtex Medical Limited, Theragenics Corporation, RaySearch Laboratories, Nanobiotix SA, CIVCO Medical Solutions, Eckert Ziegler Bebig GmbH, iCAD Inc., IsoAid, C4 Imaging LLC, Mick Radio-Nuclear Instruments Inc., Huiheng Medical Inc., Best Medical International Inc., Cianna Medical Inc.

North America was the largest region in the brachytherapy market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the brachytherapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the brachytherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Brachytherapy is a form of radiotherapy where radioactive sources are placed directly into or near the tumor, enabling targeted delivery of radiation to cancerous tissues while minimizing exposure to surrounding healthy tissues. It is widely used for treating cancers such as prostate, cervical, and skin cancers, providing a localized and effective treatment option.

The main types of brachytherapy include applicators and afterloaders, as well as electronic brachytherapy. Applicators are devices used to deliver radioactive sources directly to treatment sites, while afterloaders automate the process of placing these sources, ensuring precision and safety in brachytherapy treatments. Brachytherapy can be administered in high-dose rate (HDR) or low-dose rate (LDR), applied in treatments for prostate cancer, gynecological cancer, breast cancer, and various medical conditions. End users typically include hospitals, specialty clinics, and other healthcare facilities.

The brachytherapy market research report is one of a series of new reports that provides brachytherapy market statistics, including the brachytherapy industry's global market size, regional shares, competitors with a brachytherapy market share, detailed brachytherapy market segments, market trends and opportunities, and any further data you may need to thrive in the brachytherapy industry. This brachytherapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The brachytherapy market consists of revenues earned by entities by providing services such as treatment planning, procedure administration, and post-treatment care. The market value includes the value of related goods sold by the service provider or included within the service offering. The brachytherapy market also includes sales of radioactive seeds, applicators, imaging and planning systems, and treatment delivery systems. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.